Rhenman & Partners Asset Management Ab Bio N Tech Se Transaction History
Rhenman & Partners Asset Management Ab
- $840 Million
- Q1 2025
A detailed history of Rhenman & Partners Asset Management Ab transactions in Bio N Tech Se stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 35,750 shares of BNTX stock, worth $3.94 Million. This represents 0.39% of its overall portfolio holdings.
Number of Shares
35,750
Previous 52,750
32.23%
Holding current value
$3.94 Million
Previous $6.01 Million
45.84%
% of portfolio
0.39%
Previous 0.63%
Shares
10 transactions
Others Institutions Holding BNTX
# of Institutions
340Shares Held
40MCall Options Held
1.43MPut Options Held
1.54M-
Baillie Gifford & CO8.16MShares$899 Million0.67% of portfolio
-
Flossbach Von Storch Ag Cologne, 2M4.26MShares$469 Million1.71% of portfolio
-
Primecap Management CO Pasadena, CA4.05MShares$446 Million0.31% of portfolio
-
Black Rock Inc. New York, NY1.9MShares$209 Million0.0% of portfolio
-
Temasek Holdings (Private) LTD Singapore, U01.81MShares$199 Million0.84% of portfolio
About BioNTech SE
- Ticker BNTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 242,684,992
- Market Cap $26.7B
- Description
- BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...